Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China

Science China Life Sciences

Volumn 59, Issue 4, 2016, Pages 349-359

  Luo, Can ^a   Wei, Jianshu ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

adoptive cell therapy; chimeric antigen receptor; combination strategy; gene modification; tumor associated antigen

Indexed keywords

HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; CHINA; CLINICAL TRIAL (TOPIC); GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; MEDICAL RESEARCH; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

BIOMEDICAL RESEARCH; CHINA; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84961857119     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-016-5034-5     Document Type: Review

References (100)

1. Adusumilli, P.S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D.R., and Sadelain, M. (2014). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6, 261ra151.
2. Almåsbak, H., Walseng, E., Kristian, A., Myhre, M.R., Suso, E.M., Munthe, L.A., Andersen, J.T., Wang, M.Y., Kvalheim, G., Gaudernack, G., and Kyte, J.A. (2015). Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther 22, 391–403.
3. Anurathapan, U., Chan, R.C., Hindi, H.F., Mucharla, R., Bajgain, P., Hayes, B.C., Fisher, W.E., Heslop, H.E., Rooney, C.M., Brenner, M.K., Leen, A.M., and Vera, J.F. (2014). Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22, 623–633.
4. Barrett, D.M., Grupp, S.A., and June, C.H. (2015). Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol 195, 755–761.
5. Barrett, D.M., Singh, N., Porter, D.L., Grupp, S.A., and June, C.H. (2014). Chimeric antigen receptor therapy for cancer. Annu Rev Med 65, 333–347.
6. Beavis, P.A., Slaney, C.Y., Kershaw, M.H., Neeson, P.J., and Darcy, P.K. (2015). Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy 7, 499–512.
7. Budde, L.E., Berger, C., Lin, Y., Wang, J., Lin, X., Frayo, S.E., Brouns, S.A., Spencer, D.M., Till, B.G., Jensen, M.C., Riddell, S.R., and Press, O.W. (2013). Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 8, e82742.
8. Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M., Carroll, R.G., Riley, J.L., Pastan, I., and June, C.H. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106, 3360–3365.
9. Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E.S., Ittmann, M.M., Marchetti, D., and Dotti, G. (2015a). Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21, 524–529.
10. Caruana, I., Weber, G., Ballard, B.C., Wood, M.S., Savoldo, B., and Dotti, G. (2015b). K562-derived whole-cell vaccine enhances antitumor responses of CAR-redirected virus-specific cytotoxic T lymphocytes in vivo. Clin Cancer Res 21, 2952–2962.
11. Caruso, H.G., Hurton, L.V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., Lee, D.A., Heimberger, A.B., Champlin, R.E., and Cooper, L.J. (2015). Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res 75, 3505–3518.
12. Cheadle, E.J., Gornall, H., Baldan, V., Hanson, V., Hawkins, R.E., and Gilham, D.E. (2014). CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 257, 91–106.
13. Chmielewski, M., and Abken, H. (2015). TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15, 1145–1154.
14. Chmielewski, M., Hombach, A.A., and Abken, H. (2013). Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 4, 371.
15. Chmielewski, M., Kopecky, C., Hombach, A.A., and Abken, H. (2011). IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71, 5697–5706.
16. Couzin-Frankel, J. (2015). CANCER IMMUNOTHERAPY. Baby’s leukemia recedes after novel cell therapy. Science 350, 731.
17. Cruz, C.R. (2014). A closer look at chimeric antigen receptor specificity. Cytotherapy 16, 1323–1324.
18. Cruz, C.R., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A.J., Ito, S., Shpall, E.J., Krance, R.A., Kamble, R.T., Carrum, G., Hosing, C.M., Gee, A.P., Mei, Z., Grilley, B.J., Heslop, H.E., Rooney, C.M., Brenner, M.K., Bollard, C.M., and Dotti, G. (2013). Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965–2973.
19. Curran, K.J., Pegram, H.J., and Brentjens, R.J. (2012). Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 14, 405–415.
20. Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., Chen, M., Feng, K., Wang, Q., Zhu, H., Fu, X., Li, S., and Han, W. (2015). Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 4, e1027469.
21. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., Quintanilla, H., Halton, E., Bernal, Y., Bouhassira, D.C., Arcila, M.E., Gonen, M., Roboz, G.J., Maslak, P., Douer, D., Frattini, M.G., Giralt, S., Sadelain, M., and Brentjens, R. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6, 224ra225.
22. Deng, Z., Wu, Y., Ma, W., Zhang, S., and Zhang, Y.Q. (2015). Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 16, 1.
23. Deniger, D.C., Yu, J., Huls, M.H., Figliola, M.J., Mi, T., Maiti, S.N., Widhopf, G.F., 2nd, Hurton, L.V., Thokala, R., Singh, H., Olivares, S., Champlin, R.E., Wierda, W.G., Kipps, T.J., and Cooper, L.J. (2015). Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS One 10, e0128151.
24. Enblad, G., Karlsson, H., and Loskog, A.S. (2015). CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. Human Gene ther 26, 498–505.
25. Fedorov, V.D., Themeli, M., and Sadelain, M. (2013). PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5, 215ra172.
26. Finney, H.M., Akbar, A.N., and Lawson, A.D.G. (2003). Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR chain. J Immunol 172, 104–113.
27. Gajewski, T.F., Schreiber, H., and Fu, Y.X. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14, 1014–1022.
28. Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., and Li, Z. (2014a). Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20, 6418–6428.
29. + T cells. J Clin Invest 115, 1616–1626.
30. Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R., Gostick, E., Yu, Z., Carpenito, C., Wang, E., Douek, D.C., Price, D.A., June, C.H., Marincola, F.M., Roederer, M., and Restifo, N.P. (2011). A human memory T cell subset with stem cell-like properties. Nat Med 17, 1290–1297.
31. Gill, S., and June, C.H. (2015). Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263, 68–89.
32. Gross, G., Gorochov, G., Waks, T., and Eshhar, Z. (1989). Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 21, 127–130.
33. Guo, B., Chen, M., Han, Q., Hui, F., Dai, H., Zhang, W., Zhang, Y., Wang, Y., Zhu, H., and Han, W. (2015). CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother 61, 1–8.
34. Haynes, N.M., Snook, M.B., Trapani, J.A., Cerruti, L., Jane, S.M., Smyth, M.J., and Darcy, P.K. (2001). Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR–vs FcRI–. J Immunol 166, 182–187.
35. Hinrichs, C.S., Borman, Z.A., Gattinoni, L., Yu, Z., Burns, W.R., Huang, J., Klebanoff, C.A., Johnson, L.A., Kerkar, S.P., Yang, S., Muranski, P., Palmer, D.C., Scott, C.D., Morgan, R.A., Robbins, P.F., Rosenberg, S.A., and Restifo, N.P. (2011). Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808–814.
36. Hinrichs, C.S., and Restifo, N.P. (2013). Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 31, 999–1008.
37. Hombach, A.A., Heiders, J., Foppe, M., Chmielewski, M., and Abken, H. (2012). OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 1, 458–466.
38. Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H.E., Rooney, C.M., Brenner, M.K., and Dotti, G. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160–1170.
39. Hudecek, M., Lupo-Stanghellini, M.T., Kosasih, P.L., Sommermeyer, D., Jensen, M.C., Rader, C., and Riddell, S.R. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19, 3153–3164.
40. John, L.B., Devaud, C., Duong, C.P., Yong, C.S., Beavis, P.A., Haynes, N.M., Chow, M.T., Smyth, M.J., Kershaw, M.H., and Darcy, P.K. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19, 5636–5646.
41. Johnson, L.A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P.R., McGettigan, S.E., Nace, A.K., Dentchev, T., Thekkat, P., Loew, A., Boesteanu, A.C., Cogdill, A.P., Chen, T., Fraietta, J.A., Kloss, C.C., Posey, A.D., Jr., Engels, B., Singh, R., Ezell, T., Idamakanti, N., Ramones, M.H., Li, N., Zhou, L., Plesa, G., Seykora, J.T., Okada, H., June, C.H., Brogdon, J.L., and Maus, M.V. (2015). Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 7, 275ra222.
42. Joyce, J.A., and Fearon, D.T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80.
43. Kakarla, S., and Gottschalk, S. (2014). CAR T cells for solid tumors: armed and ready to go–Cancer J 20, 151–155.
44. Kenderian, S.S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V., Morrissette, J.J., Scholler, J., Song, D., Porter, D.L., Carroll, M., June, C.H., and Gill, S. (2015). CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29, 1637–1647.
45. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M., and Sadelain, M. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31, 71–75.
46. Krug, C., Wiesinger, M., Abken, H., Schuler-Thurner, B., Schuler, G., Dorrie, J., and Schaft, N. (2014). A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother 63, 999–1008.
47. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A., and Mackall, C.L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195.
48. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S., and Mackall, C.L. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528.
49. Liu, K., Liu, X., Peng, Z., Sun, H., Zhang, M., Zhang, J., Liu, S., Hao, L., Lu, G., Zheng, K., Gong, X., Wu, D., Wang, F., and Shen, L. (2015a). Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging. Oncotarget 6, 23735–23747.
50. Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E.C., Cogdill, A.P., Li, N., Ramones, M., Granda, B., Zhou, L., Loew, A., Young, R.M., June, C.H., and Zhao, Y. (2015b). Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 75, 3596–3607.
51. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., Kaplan, R.N., Patterson, G.H., Fry, T.J., Orentas, R.J., and Mackall, C.L. (2015). 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21, 581–590.
52. Mahoney, K.M., Rennert, P.D., and Freeman, G.J. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14, 561–584.
53. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L., and Grupp, S.A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371, 1507–1517.
54. Maude, S.L., Teachey, D.T., Porter, D.L., and Grupp, S.A. (2015). CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017–4023.
55. Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., Savino, B., Colombo, P., Jonjic, N., Pecanic, S., Lazzarato, L., Fruttero, R., Gasco, A., Bronte, V., and Viola, A. (2011). Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208, 1949–1962.
56. Moon, E.K., Carpenito, C., Sun, J., Wang, L.C., Kapoor, V., Predina, J., Powell, D.J., Riley, J.L., June, C.H., and Albelda, S.M. (2011). Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17, 4719–4730.
57. Moon, E.K., Wang, L.C., Dolfi, D.V., Wilson, C.B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Pure, E., Milone, M.C., June, C.H., Riley, J.L., Wherry, E.J., and Albelda, S.M. (2014). Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20, 4262–4273.
58. Morgan, R.A., Johnson, L.A., Davis, J.L., Zheng, Z., Woolard, K.D., Reap, E.A., Feldman, S.A., Chinnasamy, N., Kuan, C.T., Song, H., Zhang, W., Fine, H.A., and Rosenberg, S.A. (2012). Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Human Gene Ther 23, 1043–1053.
59. Morgan, R.A., and Kakarla, S. (2014). Genetic modification of T cells. Cancer J 20, 145–150.
60. Nakazawa, Y., Huye, L.E., Salsman, V.S., Leen, A.M., Ahmed, N., Rollins, L., Dotti, G., Gottschalk, S.M., Wilson, M.H., and Rooney, C.M. (2011). PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 19, 2133–2143.
61. Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H.E., Brenner, M.K., Rooney, C.M., and Ramos, C.A. (2015). Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905–3916.
62. Oren, R., Hod-Marco, M., Haus-Cohen, M., Thomas, S., Blat, D., Duvshani, N., Denkberg, G., Elbaz, Y., Benchetrit, F., Eshhar, Z., Stauss, H., and Reiter, Y. (2014). Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds. J Immunol 193, 5733–5743.
63. Perna, S.K., Pagliara, D., Mahendravada, A., Liu, H., Brenner, M.K., Savoldo, B., and Dotti, G. (2014). Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 20, 131–139.
64. Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., Lebuhotel, C., Eyquem, J., Cheung, G.W., Duclert, A., Gouble, A., Arnould, S., Peggs, K., Pule, M., Scharenberg, A.M., and Smith, J. (2015b). Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. Cancer research.
65. Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., Gonzalez, V., Ambrose, D., Grupp, S.A., Chew, A., Zheng, Z., Milone, M.C., Levine, B.L., Melenhorst, J.J., and June, C.H. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7, 303ra139.
66. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H., Liu, E., Gee, A.P., Mei, Z., Yvon, E., Weiss, H.L., Liu, H., Rooney, C.M., Heslop, H.E., and Brenner, M.K. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14, 1264–1270.
67. Ramanayake, S., Bilmon, I., Bishop, D., Dubosq, M.C., Blyth, E., Clancy, L., Gottlieb, D., and Micklethwaite, K. (2015). Low-cost generation of good manufacturing practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials. Cytotherapy 17, 1251–1267.
68. Rosenberg, S.A., and Restifo, N.P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68.
69. Sadelain, M. (2015). CAR therapy: the CD19 paradigm. J Clin Invest 125, 3392–3400.
70. Sadelain, M., Brentjens, R., and Riviere, I. (2013). The basic principles of chimeric antigen receptor design. Cancer Discov 3, 388–398.
71. Shen, C.J., Yang, Y.X., Han, E.Q., Cao, N., Wang, Y.F., Wang, Y., Zhao, Y.Y., Zhao, L.M., Cui, J., Gupta, P., Wong, A.J., and Han, S.Y. (2013). Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J Hematol Oncol 6, 33.
72. Singh, H., Figliola, M.J., Dawson, M.J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D.A., Champlin, R.E., and Cooper, L.J. (2011). Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71, 3516–3527.
73. Singh, H., Moyes, J.S., Huls, M.H., and Cooper, L.J. (2015). Manufacture of T cells using the sleeping beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther 22, 95–100.
74. Song, D.G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.P., Ji, C., Figini, M., June, C.H., Coukos, G., and Powell, D.J. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 71, 4617–4627.
75. Song, D.G., Ye, Q., Poussin, M., Harms, G.M., Figini, M., and Powell, D.J., Jr. (2012). CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119, 696–706.
76. Song, D.G., Ye, Q., Poussin, M., Liu, L., Figini, M., and Powell, D.J. (2015). A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 6, 21533–21546.
77. Srivastava, S., and Riddell, S.R. (2015). Engineering CAR-T cells: design concepts. Trends Immunol 36, 494–502.
78. Tan, K.W., Evrard, M., Tham, M., Hong, M., Huang, C., Kato, M., Prevost-Blondel, A., Donnadieu, E., Ng, L.G., and Abastado, J.P. (2015). Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment. Oncoimmunology 4, e978709.
79. Tang, X., Zhou, Y., Li, W., Tang, Q., Chen, R., Zhu, J., and Feng, Z. (2014). T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res 28, 468–475.
80. + T cells derived from virus-specific central memory T cells. Blood 119, 72–82.
81. Turtle, C.J. (2013). Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int J Hematol 99, 132–140.
82. Valton, J., Guyot, V., Marechal, A., Filhol, J.M., Juillerat, A., Duclert, A., Duchateau, P., and Poirot, L. (2015). A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol Ther 23, 1507–1518.
83. van der Stegen, S.J.C., Hamieh, M., and Sadelain, M. (2015). The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 14, 499–509.
84. van der Waart, A.B., Hobo, W., and Dolstra, H. (2015). Time to: superior tumor-reactive T cells for adoptive immunotherapy. Oncoimmunology 4, e1003016.
85. van der Waart, A.B., van de Weem, N.M., Maas, F., Kramer, C.S., Kester, M.G., Falkenburg, J.H., Schaap, N., Jansen, J.H., van der Voort, R., Gattinoni, L., Hobo, W., and Dolstra, H. (2014). Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 124, 3490–3500.
86. Wang, C., Hu, W., Shen, L., Dou, R., Zhao, S., Shan, D., Yu, K., Huang, R., and Li, H. (2014a). Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells. J Immunother 37, 351–359.
87. Wang, D., Zhang, L., Li, Y., Wang, H., Xiao, Q., Cao, W., and Feng, W. (2012a). Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells. Biotechnol Lett 34, 1193–1201.
88. Wang, Q.S., Wang, Y., Lv, H.Y., Han, Q.W., Fan, H., Guo, B., Wang, L.L., and Han, W.D. (2015). Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23, 184–191.
89. Wang, W., Ma, Y., Li, J., Shi, H.S., Wang, L.Q., Guo, F.C., Zhang, J., Li, D., Mo, B.H., Wen, F., Liu, T., Liu, Y.T., Wang, Y.S., and Wei, Y.Q. (2013). Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther 20, 970–978.
90. Wang, X., Naranjo, A., Brown, C.E., Bautista, C., Wong, C.W., Chang, W.C., Aguilar, B., Ostberg, J.R., Riddell, S.R., Forman, S.J., and Jensen, M.C. (2012c). Phenotypic and functional attributes of lentivirusmodified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 35, 689–701.
91. Wang, Y., Zhang, W.Y., Han, Q.W., Liu, Y., Dai, H.R., Guo, Y.L., Bo, J., Fan, H., Zhang, Y., Zhang, Y.J., Chen, M.X., Feng, K.C., Wang, Q.S., Fu, X.B., and Han, W.D. (2014d). Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 155, 160–175.
92. Weibo, P., and Zhaoming, Y. (2012). Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma. Med Hypotheses 78, 616–618.
93. Wu, C.Y., Roybal, K.T., Puchner, E.M., Onuffer, J., and Lim, W.A. (2015a). Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077.
94. Wu, Y., Deng, Z., Tang, Y., Zhang, S., and Zhang, Y.Q. (2015b). Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity. BMC Cancer 15, 603.
95. Xu, Y., Zhang, M., Ramos, C.A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C.J., Gee, A.P., Heslop, H.E., Rooney, C.M., Savoldo, B., and Dotti, G. (2014). Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750–3759.
96. Yang, Y. (2015). Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 125, 3335–3337.
97. Zhao, Q., Ahmed, M., Tassev, D.V., Hasan, A., Kuo, T.Y., Guo, H.F., O’Reilly, R.J., and Cheung, N.K. (2015a). Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia 29, 2238–2247.
98. Zhao, Z., Condomines, M., van der Stegen, S.J., Perna, F., Kloss, C.C., Gunset, G., Plotkin, J., and Sadelain, M. (2015b). Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415–428.
99. Zheng, Y., Yu, K., Du, J., Jiang, L., Zhang, S., Han, Y., Yu, P., and Tan, Y. (2010). Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells. J Exp Clin Cancer Res 29, 121.
100. Zhou, X., Li, J., Wang, Z., Chen, Z., Qiu, J., Zhang, Y., Wang, W., Ma, Y., Huang, N., Cui, K., Li, J., and Wei, Y.-Q. (2013). Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 15, 544-IN521.